Alfonso Fasano, MD, PhD, University of Toronto, Toronto, Canada, highlights two research tracks within the movement disorders field that require attention—finding cures and designing more effective symptomatic therapies. Discovering methods of slowing or preventing disease progression is the ultimate goal. However, Dr Fasano expresses concerns that restricting focus to hunting for a cure could mean reduced time and funding dedicated to the development of symptomatic treatments that would benefit many patients with movement disorders. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.
Dr Fasano reports the following disclosures: Receipt of grants/research support: Boston Scientific, MJ Fox Foundation, Medtronic, University of Toronto, McLaughlin Centre Receipt of honoraria or consultation fees: Abbott, Abbvie, American Academy of Neurology, Brainlab, Boston Scientific, Ceregate, Chiesi Farmaceutici, Inbrain, International Parkinson and Movement Disorder Society, Ipsen, Medtronic, Novartis, TEVA Canada, UCB pharma, Sunovion Participation in a company sponsored advisory board: Abbott, Abbvie, Boston Scientific, Ipsen, Medtronic, Sunovion